1675201-83-8

Basic information

• Product Name: 2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)-
• Synonyms: 2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)-;PD1-PDL1 inhibitor 1;PD-1PD-L1 inhibitor;(2S)-1-[[2,6-Dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-2-piperidinecarboxylic acid;avelumab/PD-L1;PD1-PDL1 inhibitor 1 (PD1-PDL1-IN1);(2S)-1-{2,6-Dimethoxy-4-[(2-methyl-3-biphenylyl)methoxy]benzyl}-2-piperidinecarboxylic acid
• CAS NO: 1675201-83-8
• Molecular Formula: C29H33NO5
• Molecular Weight: 475.57602
• EINECS: -0
• Mol File: 1675201-83-8.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 630.2±55.0 °C(Predicted)
• Appearance: /
• Density: 1.182±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C
• Solubility: Soluble in DMSO (up to at least 25 mg/ml) or in Ethanol (up to 20 mg/ml)
• PKA: 2.34±0.20(Predicted)
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
• CAS DataBase Reference: 2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)-(1675201-83-8)
• EPA Substance Registry System: 2-Piperidinecarboxylic acid, 1-[[2,6-dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-, (2S)-(1675201-83-8)

Safety Data

• Hazardous Substances Data: 1675201-83-8(Hazardous Substances Data)

Usage

Description

PD-1/PD-L1 Inhibitor 1 (1675201-83-8) inhibits (IC50 = <100nM) the formation of the PD-1/PD-L1 complex via binding to PD-L1 and inducing dimerization.1

Uses

BMS-1 is a PD-L1 inhibitor which is used in combination with LIF inhibitors for the treatment of cancers.

in vitro

pd-1/pd-l1 inhibitor 1 has been identified to be a potent and selective small molecule inhibitor blocking the interaction of programmed cell death protein 1 (pd-1) with its ligand protein (pd-l1). pd-1/pd-l1 inhibitor 1 was also found to act as an immunomodulator. in preclinical studies, pd-1/pd-l1 inhibitor 1 was able to block pd-1/pd-ll interactions with an ic50 value between 6 and 100 nm, which was measured by a homogenous time-resolved fluorescence (htrf) binding assay. thus, pd-1/pd-l1 inhibitor 1 might potentially be used for the treatment of cancer as well as infectious diseases, such as hepatitis c [1].

IC 50

0.006-0.10 μm

References

1) Chupak?et al. (2015), Compounds Useful as Immunomodulators; WO2015/034820

Upstream product

• 3105-95-1 pipecolinic acid 
• 76350-90-8 (2-methyl-[1,1′-biphenyl]-3-yl)methanol 
• 83647-43-2 3-bromo-2-methylbenzyl alcohol 
• 98-80-6 phenylboronic acid 

Relevant articles and documents

COMPOUNDS WITH IMMUNOMODULATORY ACTIVITY AND THERAPEUTIC USES THEREOF

The present invention generally relates to new compounds for therapeutic uses. In particular, the disclosed series compounds with immunomodulatory activities are useful for treatment of dysfunctions of the immune system and various cancers. Pharmaceutical composition matters and methods for treating a patient with an immune disease and/or a cancer by administering therapeutically effective amounts of such compound alone or together with other therapeutics are within the scope of this disclosure.